Journal of Clinical Oncology, Vol 10, 520-528, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

DI Jodrell, MJ Egorin, RM Canetta, P Langenberg, EP Goldbloom, JN Burroughs, JL Goodlow, S Tan and E Wiltshaw
Division of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.

PURPOSE: The study was undertaken to define the relationship between tumor response and carboplatin area under the curve (AUC) in patients with ovarian cancer; to study the relationship between carboplatin AUC and myelosuppression in the same population; to establish the true impact of carboplatin AUC, prior therapy, and pretreatment platelet and WBC counts on toxicity; and to define an optimal carboplatin exposure for treating patients with ovarian cancer. METHODS: With the equation AUC = dose/(glomerular filtration rate [GFR]+25), carboplatin AUC (course 1) was calculated for 1,028 patients (450 previously untreated) who received single-agent carboplatin (40 to 1,000 mg/m2) for advanced ovarian cancer. GFR was measured (chromium-51-edathamil [51Cr-EDTA] or creatinine clearance) in all patients. RESULTS: Regression analysis showed that carboplatin AUC, prior treatment, and Eastern Cooperative Oncology Group grade performance status (PS) are predictors of tumor response, thrombocytopenia, and leukopenia. Pretreatment platelet and WBC counts are additional predictors of thrombocytopenia and leukopenia, respectively. Although the likelihood of tumor response increased with increasing carboplatin AUC, this relationship was nonlinear. In all patient subsets, the likelihood of complete response (CR) or overall response did not increase significantly above a carboplatin AUC of 5 to 7 mg/mL x minutes. At any given carboplatin AUC, thrombocytopenia occurred more frequently than leukopenia, although both approached 100% as carboplatin AUC increased. Both thrombocytopenia and leukopenia were more frequent in pretreated than in untreated patients regardless of pretreatment count. At any carboplatin AUC, the influence of PS on likelihood of response and toxicity was profound. CONCLUSION: Carboplatin dosing by AUC will lead to more predictable toxicity, and increasing carboplatin AUC above 5 to 7 mg/mL x minutes does not improve the likelihood of response but does increase myelotoxicity. Therefore, careful evaluation of high-dose carboplatin therapy in a prospective, randomized trial is needed before such treatment becomes accepted practice.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. S Shord, L. R Bressler, L. Radhakrishnan, N. Chen, and J L. Villano Evaluation of the Modified Diet in Renal Disease Equation for Calculation of Carboplatin Dose Ann. Pharmacother., February 1, 2009; 43(2): 235 - 241. [Abstract] [Full Text] [PDF]

				K. Holweger, H.-P. Lipp, K. Dietz, J. T. Hartmann, and C. Bokemeyer Novel Algorithm for More Accurate Calculation of Renal Function in Adults with Cancer Ann. Pharmacother., December 1, 2008; 42(12): 1749 - 1757. [Abstract] [Full Text] [PDF]

				S. V. Barrett, J. Paul, A. Hay, P. A. Vasey, S. B. Kaye, R. M. Glasspool, and On behalf of the Scottish Gynaecological Cancer Tr Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Ann. Onc., May 1, 2008; 19(5): 898 - 902. [Abstract] [Full Text] [PDF]

				L. Alnaim Therapeutic drug monitoring of cancer chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 207 - 221. [Abstract] [PDF]

				R. F. Ozols Ovarian Cancer: Is Dose Intensity Dead? J. Clin. Oncol., September 20, 2007; 25(27): 4157 - 4158. [Full Text] [PDF]

				S. Kaestner and G. Sewell Dose-banding of carboplatin: rationale and proposed banding scheme Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 109 - 117. [Abstract] [PDF]

				H. K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, R. Sayer, J. Cragun, J. Clarke, R. S. Whitaker, L. Li, et al. An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., February 10, 2007; 25(5): 517 - 525. [Abstract] [Full Text] [PDF]

				C. Kloft, J. Wallin, A. Henningsson, E. Chatelut, and M. O. Karlsson Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs. Clin. Cancer Res., September 15, 2006; 12(18): 5481 - 5490. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				M. Gore Carboplatin Equals Cisplatin: But How Do I Prescribe It? J. Clin. Oncol., September 1, 2003; 21(17): 3183 - 3185. [Full Text] [PDF]

				J. Alexandre, M. Gross-Goupil, B. Falissard, M.-L. Nguyen, J.-M. Gornet, J.-L. Misset, and F. Goldwasser Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy Ann. Onc., January 1, 2003; 14(1): 36 - 41. [Abstract] [Full Text] [PDF]

				C. J. Dunton Management of Treatment-Related Toxicity in Advanced Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 11 - 19. [Abstract] [Full Text] [PDF]

				H. I. Robins, S. M. Chang, M. D. Prados, W.K. A. Yung, K. Hess, D. Schiff, H. Greenberg, K. Fink, K. Nicolas, J. G. Kuhn, et al. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study Neuro-oncol, April 1, 2002; 4(2): 109 - 114. [Abstract] [PDF]

				R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis J. Clin. Oncol., March 1, 2002; 20(5): 1248 - 1259. [Abstract] [Full Text] [PDF]

				G. J. Veal, C. Dias, L. Price, A. Parry, J. Errington, J. Hale, A. D. J. Pearson, A. V. Boddy, D. R. Newell, and M. J. Tilby Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2205 - 2212. [Abstract] [Full Text] [PDF]

				W. C. Zamboni, D. Z. D'Argenio, C. F. Stewart, T. MacVittie, B. J. Delauter, A. M. Farese, D. M. Potter, N. M. Kubat, D. Tubergen, and M. J. Egorin Pharmacodynamic Model of Topotecan-induced Time Course of Neutropenia Clin. Cancer Res., August 1, 2001; 7(8): 2301 - 2308. [Abstract] [Full Text] [PDF]

				M. Ando, H. Minami, Y. Ando, H. Saka, S. Sakai, M. Yamamoto, Y. Sasaki, K. Shimokata, and Y. Hasegawa Multi-Institutional Validation Study of Carboplatin Dosing Formula Using Adjusted Serum Creatinine Level Clin. Cancer Res., December 1, 2000; 6(12): 4733 - 4738. [Abstract] [Full Text]

				H. Thomas, A. V. Boddy, M. W. English, R. Hobson, J. Imeson, I. Lewis, B. Morland, A. D. J. Pearson, R. Pinkerton, L. Price, et al. Prospective Validation of Renal Function-Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children's Cancer Study Group Trial J. Clin. Oncol., November 1, 2000; 18(21): 3614 - 3621. [Abstract] [Full Text] [PDF]

				P. G. Rose, M. Rodriguez, S. Waggoner, B. E. Greer, I. R. Horowitz, J. M. Fowler, and W. P. McGuire Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., August 16, 2000; 18(16): 2957 - 2962. [Abstract] [Full Text] [PDF]

				M. Fukuda, M. Oka, H. Soda, K. Terashi, S. Kawabata, K. Nakatomi, H. Takatani, J. Tsurutani, K. Tsukamoto, Y. Noguchi, et al. Phase I Study of Irinotecan Combined with Carboplatin in Previously Untreated Solid Cancers Clin. Cancer Res., December 1, 1999; 5(12): 3963 - 3969. [Abstract] [Full Text] [PDF]

				H. Okamoto, K. Watanabe, Y. Nishiwaki, K. Mori, Y. Kurita, I. Hayashi, M. Masutani, K. Nakata, S. Tsuchiya, H. Isobe, et al. Phase II Study of Area Under the Plasma-Concentration-Versus-Time Curve-Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly Patients With Small-Cell Lung Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3540 - 3545. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky, M. Jiroutek, P. Bonomi, D. Johnson, and S. D. Baker Paclitaxel Steady-State Plasma Concentration as a Determinant of Disease Outcome and Toxicity in Lung Cancer Patients Treated with Paclitaxel and Cisplatin Clin. Cancer Res., April 1, 1999; 5(4): 767 - 774. [Abstract] [Full Text] [PDF]

				S. O'Reilly Topotecan: What Dose, What Schedule, What Route? Clin. Cancer Res., January 1, 1999; 5(1): 3 - 5. [Full Text] [PDF]

				D. Armstrong and S. O'Reilly Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity Oncologist, February 1, 1998; 3(1): 4 - 10. [Abstract] [Full Text]

				D. S. Alberts and R. T. Dorr New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors Oncologist, February 1, 1998; 3(1): 15 - 34. [Abstract] [Full Text]

				M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider Dose Intensity of Chemotherapy for Childhood Cancers Oncologist, October 1, 1996; 1(5): 293 - 304. [Abstract] [Full Text] [PDF]

				S. A. Cannistra Cancer of the Ovary N. Engl. J. Med., November 18, 1993; 329(21): 1550 - 1559. [Full Text]